SuperSonic Imagine Announces the Recognition of ShearWave(TM) Elastography's Exceptional Clinical Value in Mettler Institute's Award Winning Presentation

AIX-EN-PROVENCE, FRANCE--(Marketwired - Oct 13, 2015) - SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, announced today that its proprietary ShearWave™ Elastography technology was the subject of an award winning presentation by the Mettler Institute at the 2015 International Fascia Research Congress (FRC) held in Washington, D.C. on September 18th - 20th. The Institute was awarded second place for overall clinical usefulness for its presentation entitled "Use of High Frequency ShearWave™ Elastography (HFSWE) to Identify and Evaluate Treatment of Fascial Adhesions."

The FRC was created by a multidisciplinary committee of basic science researchers and practicing health care professionals whose respective fields share a common focus and interest in the human body's soft connective tissue matrix. The Congress, which was attended by over 1,000 participants in 2015, has built a reputation for bringing cutting-edge fascia science to the research, medical and clinical communities. An important continued initiative of the FRC is to foster understanding and collaboration among scientists working in fascia research and the various clinical professionals who address fascia in their work with clients and patients.

ShearWave Elastography is a non-invasive exam that provides real time, color-coded maps with quantitative measurements of musculoskeletal (MSK) stiffness that help assess MSK disease and guide treatment. High frequency ultrasound can evaluate the effectiveness of altering tissue stiffness in tendons and myofascial tissue with dry needling and other manual therapies. Mettler's presentation described the broader applications of ShearWave Elastography in the evaluation of treatment effectiveness in reducing myofascial stiffness.

HFSWE was used to quantify tissue condition at the beginning, middle and end of therapy. HFSWE provided a method to visualize fascial adhesions in real time and identified areas of increased tissue stiffness with widespread fascial adhesions. Results guided manual treatment to reduce both tissue stiffness and pain. Therapists were able to improve their effectiveness using objective tools to measure treatment outcomes, which offer qualitative and quantitative monitoring of tissue stiffness following therapy or surgery.

About the Mettler Institute for Physical Therapy
Over the past 20 years, Paul R. Mettler, PT, DPT has developed a new technique to treat a wide range of acute and chronic injuries. The Mettler Method allows for the successful identification and treatment of adhesive scar tissue. Dermo-Myofascial Release(SM)is a new manual approach for addressing the effect of inflammatory processes on the musculoskeletal system. Recent advances in ultrasound diagnostic technology in the field of internal medicine, clinical dermatology and more recently physical therapy are helping understand this process and why this advanced manual therapy (DMR) is so effective at restoring health to the dermis and underlying myofascia. Through real-time imaging, Dr. Mettler and his associates have been able to confirm how DMR systematically and progressively frees skin and myofascia stiffness or adhesions caused by tissue inflammation.

About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer^®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer^® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer^® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.com